Acquired epithelial Wnt7b secretion establishes autocrine WNT dependency in BRAF mutant colorectal cancer
Colorectal cancer (CRC) subtypes differ fundamentally in their reliance on WNT signaling, yet the sources and regulation of WNT ligands as well as the subtype-specific requirements for ligand-driven activation remain poorly defined. Here, we generated genetically-engineered organoid models of Apc- and Braf-mutant CRC to systematically dissect ligand dependency across distinct genetic backgrounds and CRC subtypes. Through genetic perturbation and pharmacological inhibition of WNT secretion, we find that BRAF-driven organoids critically depend on autocrine WNT ligand production for survival and proliferation. In contrast, APC-mutant organoids remain viable but undergo discernible transcriptional changes upon ligand withdrawal. We identify Wnt7b as a non-redundant epithelial WNT ligand required to sustain beta-catenin-dependent signaling specifically in BRAF-mutant CRC. Chromatin accessibility and transcriptional profiling reveal that Wnt7b activation occurs early during transformation and coincides with cancer-specific opening of regulatory elements at the Wnt7b locus. Integrative regulatory analyses nominate the transcription factor RFX7 as a candidate upstream regulator of epithelial Wnt7b expression. Consistent with these findings, analysis of human CRC specimens demonstrates WNT7B expression in a subset of BRAF-mutant tumors and reveals an association with poor patient survival. Together, these results redefine ligand dependency in colorectal cancer and uncover autocrine WNT7B signaling as a mechanistically defined vulnerability in aggressive BRAF-mutant disease.